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IL-10 is a regulatory cytokine that plays a major role in the homeostasis of the gut and this is illustrated by the fact that IL-
10−/− mice develop spontaneous colitis. In this study, IL-10−/− mice were analyzed for immunological changes during colitis
development. We found a reduced frequency of regulatory T cells CD4+CD25+Foxp3+ and higher frequency of activated T
cells in the colon that precedes the macroscopic signs of the disease. Production of IL-17 and IFN-γ was higher in the colon.
Colitis progression culminates with the reduction of CD4+LAP
+ regulatory T cells in the intestine. Frequency of B1 cells and the
secretory IgA production were both elevated. Despite these alterations, 16-week-old IL-10−/− m i c ec o u l db er e n d e r e dt o l e r a n tb y
a continuous feeding protocol. Our study provides detailed analysis of changes that precede colitis and it also suggests that oral
tolerance could be used to design novel alternative therapies for the disease.
1.Introduction
The intestine is the largest surface of contact between the
body and the external environment [1]. Most contacts with
foreign antigenic materials occur at the gut mucosa. It has
been reported that 130–190g of protein is absorbed in the
small intestine daily [2] and the gastrointestinal tract har-
boursapproximately1014 microorganismsofmorethan1000
species mostly in the colon [3]. All these antigenic contacts
play an important role in the development of the immune
system. Mice reared from weaning up to adulthood on a
diet containing exclusively amino acids as nitrogen source
have a drastic reduction in the gut-associated lymphoid
tissue and in IgG/IgA production with an immunological
phenotype that resembles suckling mice [4]. Germ-free
mice display similar immunological alterations [5]. Under
physiological conditions, the constant exposure to these
natural antigens through the gut mucosa leads to local
and systemic immunological activities, such as secretory
immunoglobulin A (sIgA) production and oral tolerance
induction [6].
Oral tolerance has classically been deﬁned as the speciﬁc
suppression of cellular and/or humoral immune responses
to an antigen previously given by the oral route [7]. Several
mechanisms have been proposed for the development of oral
tolerance, ranging from the deletion of antigen-speciﬁc T
cells to immune deviation and suppression by regulatory
T cells [6] .S t u d i e si nb o t hm o u s em o d e l sa n dh u m a n2 Clinical and Developmental Immunology
tissues have suggested that inﬂammatory bowel disease
(IBD) is a consequence of the breakdown of normal mucosal
tolerance to luminal antigens. Chronic inﬂammatory bowel
diseases are thought to arise from interacting genetic and
environmental factors including altered T cell responses
to intestinal antigens [8, 9]. Tolerance to autochthonous
microbiota seems to be broken in individuals with IBD
providing evidence that inﬂammatory reactivity to ubiqui-
tous antigens from microbiota is implicated in the initiation
and/or perpetuation of IBD [10].
Several murine models of colitis have highlighted the
important role that abnormalities of the immune system,
particularlythoseaﬀectingTcells,mayplayindiseasepatho-
genesis. These models include rats carrying the transgenes
for HLA B27 and β2-microglobulin, and mice in which the
genes coding IL-2, IL-10, and α or β chains of T cell receptors
are absent [8]. In the same line, studies using T cell-restored
immunodeﬁcient mice have provided evidence that CD4+
T cells play a key role in the induction and regulation of
intestinalinﬂammation.CelltransferofCD45RBhigh CD4+ T
cells from normal mice donors into C.B-17 severe combined
immunodeﬁcient (SCID) mice led to the development of a
severe inﬂammatory response in the colon [11]. The disease
can be prevented by cotransfer of the CD45RBlow subset and
interleukin IL-10 is an essential mediator produced by this
regulatory T cell population [12].
I L - 1 0i sp r o d u c e db yr e g u l a t o r yTc e l l sa n dav a r i e t yo f
other cell types including epithelia, activated macrophages,
dendritic cells, and B1 cells. IL-10 is a key immunosup-
pressive cytokine that acts directly on antigen-presenting
cells (APC) to inhibit IL-12 secretion and down regulate the
expression of MHC-II as well as costimulatory molecules
such as CD80 and CD86 [13]. This modulatory action on
APC indirectly inhibits T cell activation. Some studies have
also suggested that IL-10 is a potent costimulant of B-
cell diﬀerentiation and immunoglobulin secretion [14]. The
importance of this cytokine in shaping mucosal immune
responses has been demonstrated by the spontaneous onset
of gut inﬂammation in the IL-10-deﬁcient (IL-10−/−)m o u s e
[15].
Under conventional conditions, IL-10−/− mice develop
chronic enterocolitis by 2-3 months of age and there is no
evidence of disease in neonates. The disease is characterized
by weight loss, splenomegaly, and mild-to-moderate anemia.
Ifmaintainedunderspeciﬁcpathogen-free(SPF)conditions,
mice develop a limited form of colitis [16]. The typical in-
ﬂammatory lesion found is discontinuous and transmural,
aﬀecting usually the lower gastrointestinal tract, with being
the small intestine much less aﬀected. Other pathological
changes include epithelial hyperplasia, mucin depletion,
crypt abscesses, ulcers, and thickening of bowel wall. The
inﬂammatoryinﬁltrateconsistsoflymphocytes,plasmacells,
macrophages, eosinophils, and neutrophils [15]. Develop-
mentofcolitisinIL-10−/− appearstobemediatedbyCD4+ T
cells and an uncontrolled Th1 response [17]. In addition, the
overproduction of numerous inﬂammatory mediators such
as IL-1β, IL-6, tumor necrosis factor (TNF)-α, as found in
cultures of mice with colitis [18].
In spite of the fact that enterocolitis in IL-10−/− mice
display features atypical of Crohn’s disease including marked
crypt hyperplasia, the rare occurrence of granulomas, ﬁbro-
sis, and the absence of ﬁssures and ﬁstulae, this experimental
model resembles Crohn’s disease in the transmural and
discontinuous inﬂammation. This inﬂammation can aﬀect
not only the colon but also the small intestine [19]. In
fact, Crohn’s disease in humans may aﬀect any segment of
the digestive tract but most frequently involves the small
intestine [20].
This study aimed to characterize morphological and
immunological alterations in gut mucosa of IL-10−/− at 6,
10, or 16 weeks of ages, covering a period since the onset
of symptoms until established enterocolitis. We analysed the
inﬂammatory features of each stage of the disease as well
as putative changes in immunoregulatory mechanisms that
may be involved. Since most of genetically deﬁcient animals
usedasexperimentalmodelsforIBDarebornwithoutcolitis
signs [21, 22], they constitute an opportunity to study the
immunological changes preceding the disease.
2.MaterialandMethods
2.1. Animals. Wild-type (WT) and IL-10-deﬁcient (IL-
10−/−) mice on a 129Sv/Ev background were obtained from
Donna-Marie McCaﬀerty’s laboratory (Calgary University,
Calgary, Canada). All mice were bred and housed in our
facility at Universidade Federal de Minas Gerais, Brazil.
Mice were kept in microisolators with autoclaved standard
chow and water until weaning. After weaning, all mice
were maintained in a conventional facility (open cages).
Animals were studied at 6, 10, and 16 weeks of age and
age-matched wild-type 129Sv/Ev mice were used as controls.
All procedures were approved by the local ethical committee
for animal research (Protocol no. 170/2008, CETEA-UFMG,
Brazil).
2.2. Macroscopic and Microscopic Assessment of Colitis. The
colon was excised and colonic inﬂammation assessed using a
previously deﬁned scoringsystem, which includes features of
clinical colitis, such as the presence or absence of adhesions,
stricturesanddiarrhea(diarrheawasdeﬁnedasloose,watery
stool), and the bowel wall thickness (measured in mm).
Samples of colon were ﬁxed in formalin and processed for
microscopic analysis. Hematoxylin-eosin-stained sections
were blindly scored based on a semiquantitative scoring
system described previously [23] where the following fea-
tures were graded: extent of destruction of normal mucosal
architecture (0: normal; 1, 2, and 3: mild, moderate, and
extensive damage, resp.), presence and degree of cellular
inﬁltration (0: normal; 1, 2, and 3: mild, moderate, and
transmural inﬁltration, resp.), extent of muscle thickening
(0: normal; 1, 2 and 3: mild, moderate and extensive
thickening, resp.), presence or absence of crypt abscesses (0:
absent; 1: present) and the presence or absence of goblet cell
depletion (0: absent; 1: present). Scores for each feature were
summed up to a maximum possible score of 11.Clinical and Developmental Immunology 3
2.3. Intestinal Tissue Preparation and Cytokine Assay. The
intestine was separated into duodenum, proximal jejunum,
distal jejunum, ileum, and colon and placed in buﬀer
solution (1mL/0.1g). Tissue fragments were homogenized
and centrifuged for 10 minutes 600g at 4◦C. Supernatants
were collected for cytokine assay. Plates were coated with
puriﬁed monoclonal antibodies reactive with cytokines IL-
17A, IL-6, TGF-β,a n dI F N - γ (BD-Pharmingen) overnight at
4◦C. In the, following day, wells were washed, supernatants
were added, and plate was incubated overnight at 4◦C. In
the third day, biotinylated monoclonal antibodies against
cytokines were added and plates were incubated for 2 hours
at room temperature. Color reaction was developed at room
temperature with 100μL/well of orthophenylenediamine
(1mg/mL), 0.04% H2O2 substrate in sodium citrate buﬀer.
Reaction was interrupted by the addition of 20μL/well of
2NH 2SO4. Absorbance was measured at 492nm by ELISA
reader (BIO-RAD).
2.4. Cell Preparation and Flow Cytometry Analysis. Intraep-
ithelial lymphocytes (IELs) were isolated by a modiﬁed
version of the method described by Davies and Parrott
[24]. Brieﬂy, the entire length of small and large intestine
were dissected, opened longitudinally, washed with PBS,
and cut into small pieces. Tissue fragments were placed
in Petri dishes and washed three times in calcium and
magnesium-free HBSS containing 2% fetal bovine serum
(FBS). After that, tissue fragments were transferred to
culture ﬂasks and incubated at 37◦C in HBSS containing
1mM DL-dithiothreitol (DTT-Sigma) for 30min, twice.
Supernatants were ﬁltered through a 70μm cell strainer and
the IEL fraction kept on ice. For lamina propria (LP) cell
isolation, tissue fragments were incubated with 100U/mL
of collagenase II (Sigma) for 60min at 37◦C in a shaker.
Supernatants were passed through a 70μm cell strainer and
then ressuspended in medium. Cells were suspended in
44% Percoll solution, which was layered on top of 67%
Percoll solution and centrifuged at 600g for 20min at
4◦C. IELs were collected from the interface between the
Percoll gradients. Cells from IEL and LP compartments were
then labelled with FITC-conjugated anti-mouse CD4, CD5
and CD25, PE-conjugated anti-mouse CD25, Thy1.2, CD44,
TCRγδ,T C R αβ and Foxp3, Cy5-conjugated anti-mouse
CD69,CD19,andBiotinanti-mouseLAP(BDPharmingen).
Cells from spleen, Peyer’s patches, peritoneum, and bone
marrow were labelled with FITC-conjugated anti-mouse
CD5 and Cy5-conjugated anti-mouse CD19. Cells were
analyzed by a FACSCan (Becton & Dickinson) and data were
analyzed by FlowJo (TreeStar). At least 30,000.00 events were
counted for each sample.
2.5. Analysis of Ig Isotypes by ELISA. Levels of Ovalbumin-
(Ova-) speciﬁc and total immunoglobulins were determined
by ELISA. Brieﬂy, 96-well plates (Nunc) were coated with
2μg/well Ova or 0.1μg goat anti-mouse UNLB antibody,
in coating buﬀer pH 9.8 overnight. Wells were washed
and blocked with 200μL of PBS contain 0.25% casein for
1h at room temperature. Sera were added to the plate
and incubated for 1h at room temperature, plates were
washed, then peroxidase-streptavidin goat anti-mouse or
rat anti-goat (Southern Biotechnology) 1:15000 was added,
and plates were incubated for 1h at 37◦C. Color reaction
w a sd e v e l o p e da tr o o mt e m p e r a t u r ew i t h1 0 0 μL/well of
orthophenylenediamine (1mg/mL) (Sigma), 0.04% H2O2
substrate in sodium citrate buﬀer. Reaction was interrupted
by the addition of 20μL/well of 2N H2SO4. Absorbance was
measured at 492nm by an ELISA microplate reader (Bio-
Rad).
2.6. Oral Tolerance Induction. Oral tolerance to Ova was
induced by intragastric administration (gavage) of a sin-
gle dose of 20mg Ova (Sigma) in 0.2mL saline (0.15M
NaCl), 7 days before primary immunization. The control
group received 0.2mL of saline. Alternatively, mice received
4mg/mL solution of Ova in water as their exclusive drinking
ﬂuid. The average voluntary intake of a mouse was about
5mL in 24h; therefore, the animals were presumed to
ingest 20mg Ova/day. Control groups received ﬁltered
tap water. Oral treatment was discontinued 7 days before
parenteral immunization. Mice were actively sensitized by an
intraperitoneal injection of 0.2mL of saline containing 10μg
of Ova adsorbed in 1mg of aluminum hydroxide. Fourteen
days later, the animals received the same dose of Ova in PBS.
2.7.StatisticalAnalysis. Resultswereexpressedasthemean±
standard error of the mean (SEM). The Kolmogorov-
Smirnov test, conﬁrmed normal distribution of samples.
Signiﬁcance of diﬀerences among groups was determined by
Student’s t-test or analysis of variance (ANOVA) (Tukey’s
posttest). Means were considered statistically diﬀerent when
P<0.05.
3. Results
3.1. Assessment of Colitis during the Course of Intestinal
Inﬂammation. Macroscopic and histology scores of colonic
mucosa were observed in 6-, 10-, or 16-week-old IL-
10−/− mice and age-matched wild-type mice. IL-10−/− mice
displayed normal colonic histological appearance at 6 weeks
of age without macroscopic signs of disease (Figures 1(b),
2(a),a n d2(b)). By 10 weeks of age, IL-10−/− mice developed
a mild colitis (Figure 1(c)), the severity of which reached a
plateau at 16 weeks of age (Figure 1(d)). The macroscopic
score did not increase after disease was established since
10- or 16-week-old IL-10−/− mice showed similar scores
(Figure 2(a)).
3.2. Morphology of Small Intestine and the IEL Proﬁle in IL-
10-Deﬁcient Mice. Regarding the impact of inﬂammatory
changes in small intestine, a previous study has described
that IL-10−/− mice can develop enteritis in conventional
conditions [15]. Histological analysis of the small intestine
revealed signals of inﬂammation only in the proximal
jejunum of 16-week-old IL-10−/− mice (Figure 1(h)). They
had altered villus/crypt ratio (Figure 2(c)) due to villus
shortening. Noteworthy, 6-weeks-old mice presented vil-
lus/crypt ratio similar to older mice (Figure 2(c)) but this4 Clinical and Developmental Immunology
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Figure 1:HistopathologyofintestinalchangesinIL-10−/− mice.(a)Histologyofproximalcolonrepresentativeofwild-type(129Sv/Ev)mice
(40x). No cellular inﬁltration between glands was found. (b) Proximal colon of 6-week-old IL-10−/− mice (40x). Mucosa and submucosa
are similar to the ones in wild-type mice. (c) Proximal colon of 10-week-old IL-10−/− mice (40x). Multifocal inﬁltrations of leucocytes in
the mucosa and submucosa. (d) Proximal colon of 16-week-old IL-10−/− mice (40x). Presence of transmural inﬂammation aﬀecting the
muscular layer can be observed. (e) Proximal jejunum representative of wild-type mice (100x). (f) Proximal jejunum of 6-week-old IL-10−/−
mice (100x). (g) Proximal jejunum of 10-week-old IL-10−/− mice (100x). (h) Proximal jejunum of 16-week-old IL-10−/− mice showing
enteritis and cellular inﬁltration in the lamina propria (asterisks) (100x). Tissues were stained with hematoxylin and eosin.
was due to higher crypt size. Intraephithelial lymphocytes
(IELs)areinvolvedinmaintenanceofintestinalepithelialcell
integrity [25]. Frequencies of TCRαβ and TCRγδ IEL popu-
lationswereanalyzedin16-week-oldIL-10−/− mice.Weused
Thy1.2 as a marker to discriminate activated IELs. Despite
the similar frequencies of TCRαβ and TCRγδ IELs, there was
a decrease in the percentage of Thy1.2+TCRγδ+ in the IEL
population in IL-10−/− mice, whereas no change was found
in the frequency of Thy1.2+TCRαβ+ IELs (Figure 2(d)).
3.3. IL-10-Deﬁcient Mice Had a Reduced Frequency of Reg-
ulatory T Cells in the Small Intestine. In agreement with
other studies, we found an increase in the frequency of
CD4+CD44+ in the colon of IL-10-deﬁcient mice at 6 and 16
weeksofagebutanonalteredfrequencyinthesmallintestine
(Figure 3(a)). There was no diﬀerence in the frequency
of T cells expressing the early activation marker CD69+
in the small and large intestine segments of either 6- or
16-week-old IL-10−/− mice when compared to their wild-
type counterparts. Of note, frequency of activated CD69+
T lymphocyte population increased with age in both wild-
type and IL-10−/− mice but only in the large intestine
(Figure 3(b)). CD4+CD25+Foxp3+ T cells were reduced in
the lamina propria of large intestine of IL-10−/− mice
regardless of their age (Figure 3(c)). The CD4+CD25+LAP+
population of lymphocytes was reduced in the small and
large intestines of IL-10−/− at 16 weeks of age. However,
the frequency of CD4+CD25+LAP+ T cells was enhanced
with age in wild-type mice in both small and large intestines
(Figure 3(d)).
3.4. Changes in Cytokine Secretion in Small and Large Intes-
tines of IL-10-Deﬁcient Mice. The cytokine proﬁle in IL-
10−/− mice was well characterized in colonic extract [18].
However, no information is available about the eﬀect of
the lack of IL-10 in the small intestine. IL-17A production
enhanced in the colon of 6-week-old IL-10-deﬁcient mice
and diminished in the duodenum of 10-week-old IL-10−/−
mice (Figure 4(a)). We found alterations in IL-6 in the distal
jejunum of IL-10−/− mice with 10 and 16 weeks of age.
Levels of IL-6 raised in the colon of 16-week-old IL-10−/−
mice (Figure 4(b)). On other hand, production of the anti-
inﬂammatory cytokine TGF-β in IL-10−/− mice increased in
the colon at 10 weeks of age and in proximal jejunum at 16
weeks of age (Figure 4(c)). 16-week-old IL-10−/− mice had
increased levels of IFN-γ in the colon (Figure 4(d)).
3.5. Frequency of B1 Lymphocytes Increased in Peritoneum
and Intestinal lamina propria of IL-10-Deﬁcient Mice with
Colitis. Since IL-10 is a potent costimulant of B cell
diﬀerentiation, immunoglobulin secretion and generation
of B1 cells [14], our next step was to investigate the
impact of IL-10 deﬁciency in B lymphocyte populations
and immunoglobulin production. There was no signiﬁcant
change in the frequency of B lymphocytes in spleen (SP),
peritoneum (PT), Peyer’s patches (PP), and gut lamina
propria (LP) but frequency of these cells was diminished in
bone marrow (BM) (Figure 5(a)). Interestingly, frequency of
B1 lymphocytes in peritoneum, Peyer’s patches, and lamina
propria of both small and large intestine was augmented in
IL-10−/− mice at 16 weeks of age (Figure 5(b)).Clinical and Developmental Immunology 5
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Figure 2: Inﬂammatory score of IL-10−/− and IEL proﬁle. (a) Macroscopic score of IL-10−/− mice at 6, 10, or 16 weeks of age and control
age-matched wild-type mice. (b) Microscopic score of IL-10−/− mice at 6, 10, or 16 weeks of age and control age-matched wild-type mice
obtained by histological analysis of the colonic tissues. (c) Villus/crypt ratio of duodenum, proximal jejunum, distal jejunum, and ileum of
IL-10−/− mice at 6, or 16 weeks of age. Bars represent the mean ± SEM of 5 mice per group. Asterisks represent diﬀerences from age matched
WT groups in the same intestinal segment (∗P<0.05 or ∗∗P<0.01). (d) Flow cytometry analysis with frequency of IEL isolated from
16-week-old IL-10−/− and control mice stained with ﬂuorescent antibodies to αβTCR, γδTCR, and Thy1.2. Cells were analyzed inside the
total lymphocytes gate. Bars represent the mean ± SEM of 3 mice per group. Signiﬁcant diﬀerence (∗∗P<0.01) is indicated by the asterisk.
n.d means non detected.
3.6. Serum Levels of Immunoglobulins Were Altered during the
Course of Disease in IL-10-Deﬁcient Mice. We investigated
whether production of the diﬀerent classes of immunoglob-
ulin was altered in IL-10-deﬁcient mice since weaning and
during the course of gut inﬂammation. There was no
diﬀerence in the serum levels of IgG, IgM, and IgA in IL-10-
deﬁcientmiceat4weeksofage(Figures5(c)–5(e)).However,
at 6 weeks of age, IL-10-deﬁcient mice had enhanced IgM
levels and reduced levels of IgG when compared to levels
found in mice at 4 weeks of age. IgA levels were unchanged
at this age (Figures 5(c)–5(e)). At 10 weeks of age, IL-10−/−
mice had higher concentration of serum IgG. Serum IgA
enhanced in IL-10−/− m i c ef r o m4t o1 0w e e k so fa g ea n d
rose again in 16 week-old mice (Figure 5(e)). Levels of IgE
were similar in all ages analysed (Figure 5(f)).
3.7. IL-10-Deﬁcient Mice with Established Gut Inﬂammation
Can Be Rendered Tolerant Only by Continuous Feeding.
Finally, we tested the impact of IL-10 deﬁciency and colitis
development in the two major immunological activities that
takeplaceatthegutmucosa:secretoryIgA(sIgA)production
and oral tolerance induction. Concentration of sIgA was
measured in the feces. Similarly to what has already been
described in the literature, IL-10−/− mice had enhanced
levels of sIgA at the time of established inﬂammation (10
weeks of age) but no diﬀerence was found in mice before
the onset of colitis at 4 or 6 weeks of age. Interestingly,
mice at 16 weeks of age with overt inﬂammation did not
show alterations in sIgA again (Figure 6(a)). To test for oral
toleranceinduction,micewereeitherfed20mgOvabyintra-
gastric administration (gavage) or given an Ova solution as6 Clinical and Developmental Immunology
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Figure 3: T lymphocyte proﬁle in the lamina propria of small and large intestine of IL-10−/− mice during the course of intestinal
inﬂammation. Lamina propria T cells from small and large intestine were obtained from either 6- or 16-week-old IL-10−/− mice. Age-
matched 129Sv/Ev (WT) mice were used as controls. Frequencies of CD4+CD44+ (a), CD4+CD69+ (b), CD4+CD25+Foxp3+ (c), and
CD4+CD25+LAP+ (d) T cells gated in CD4+ T cells were assessed by ﬂow cytometry. Bars represent the mean ± S E Mo f4m i c ep e rg r o u p .
Signiﬁcant diﬀerences (∗P<0.05, ∗∗P<0.01 or ∗∗∗P<0.001) are indicated by asterisks.
theonlyliquidsourceforoneday(continuousfeeding).They
were intraperitoneally immunized with the same antigen
in adjuvant 7 days thereafter. Levels of anti-Ova IgE were
reduced in both wild-type (129Sv/Ev) and in IL-10−/− mice
that received Ova by either continuous feeding or gavage
before immunization when compared to the immunized
group(Figure 6(b)). However, only IL-10-deﬁcient mice that
were continuously fed Ova could be rendered tolerant for
anti-Ova IgG1 production (Figure 6(c)).
4. Discussion
Mouse models of intestinal inﬂammation have played a
key role in understanding the mechanisms that govern the
inﬂammatoryresponseintheintestine,andindesigningnew
therapeutic strategies for human Crohn’s disease and ulcer-
ative colitis. Experimental models of IBD usually involve
defects in epithelial integrity/permeability or in regulatory
elements of the immune system [8]. Several pathological and
immunological changes are signiﬁcantly diﬀerent between
these models. For example, the chemical model induced by
dextran sulfate sodium (DSS) display inﬂammatory features
similar to ulcerative colitis, while in IL-10−/− the inﬂamma-
tion resembles Crohn’s disease featuring transmural inﬂam-
mation in colonic mucosa. Indeed, we found that in the IL-
10−/− m i c et h e r ew a sa no v e r p r o d u c t i o no fI F N - γ and IL-17
(Figure 4),whereasinDSS-inducedmodelofcolitisoccurred
ap r e v a l e n c eo fI L - 6 ,T N F - α,a n dI N F - γ without alterations
in IL-17 production (data not shown). Of note, we observed
reduced frequencies of regulatory T cells in mice with DSS-
induced colitis (data not shown) similarly to what was
foundinIL-10−/− mice(Figure 3).However,inDSS-induced
colitis, the earliest histological change that predated clinical
colitis was the loss of crypt epithelial cells. Inﬂammation
became signiﬁcant only after the appearance of erosions.Clinical and Developmental Immunology 7
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Figure 4: Production of cytokines in the intestinal mucosa during the course of intestinal inﬂammation. Intestines from IL-10−/− at 6, 10
or 16 weeks of age were removed, separated into duodenum, proximal jejunum, distal jejunum, ileum and homogenized in extract buﬀer.
Age-matched 129Sv/Ev (WT) mice were used as controls. Extract supernatant was collected for cytokine assay. IL-17A (a), IL-6 (b), TGF-β
(c), and IFN-γ (d) were measured by ELISA. n = 5 mice per group. Asterisks represent diﬀerences among groups in the same intestinal
segment (∗P<0.05, ∗∗P<0.01 or ∗∗∗P<0.001).
On the other hand, in IL-10-deﬁcient mice, inﬂammation
precedes the establishment of clinically detected disease and
occurred spontaneously. Therefore, the model of IL-10−/−
mouse provides an opportunity to study pathophysiology
andimmunologicalchangesthatprecedeandaccompanythe
development of the disease.
In this study we used IL-10-deﬁcient mice in the
129Sv/Evgeneticbackground.Althoughmacroscopicdisease
can be detected at 3 months of age in IL-10-deﬁcient mice,
severityofintestinallesionsvarywiththegeneticbackground
of the mice. They are most severe in 129Sv/Ev and BALB/c
strains, of intermediate severity in 129 x C57BL/6J hybrid
mice, and least severe in the C57BL/6J strain. Thus, the
129Sv/Ev strain is considered the one with highest sus-
ceptibility to colitis development with homogenous clinical
manifestations of the disease among susceptible animals
[19]. Since in SPF conditions these mice exhibited only
small lesions in the mucosa of proximal colon [16], we
chose to undertake our study with mice maintained under
conventional conditions, which lead to the full development
of enterocolitis.
At 6 weeks of age, just after weaning, no histological
sign of inﬂammation was observed in the large intestine of
these mice. On the other hand, IL-10-deﬁcient mice at 10
weeks of age showed already established enterocolitis with
inﬁltration of leucocytes in the gut mucosa and submucosa
areas. Severity of the disease progressed as they aged, and
16-week-old mice showed a transmural inﬂammation in the
colon. Parameter such as onset and severity of enterocolitis
in IL-10−/− mice varies according to the animal facility that
mice are kept. Rederivation of IL-10-deﬁcient mice from
conventional SPF environments into germ-free isolators
eliminates colitis development, clearly demonstrating the
inﬂuence of microbiota in the establishment of disease [16].8 Clinical and Developmental Immunology
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Figure 5: B cells and immunoglobulins isotype during the development of enterocolitis. Cells from spleen (SP), bone marrow (BM),
Peritoneum (PT), Peyer patches (PP), or lamina propria (LP) from small or large intestine were obtained from 16-week-old IL-10−/−
mice. Frequencies of CD19+ Bc e l l s( a )o rC D 1 9 +CD5+ (b) gated on lymphocytes or CD19+ population, respectively, were assessed by
ﬂow cytometry. Bars represent the mean ± SEM of 4 mice per group. Asterisks represent diﬀerence between groups (P<0.05). Sera from 4-,
6-, 10-, or 16-week-old IL-10−/− mice were collected and total IgM (c), IgG (d), IgA (e), and IgE (f) were measured by ELISA. A.U.: arbitrary
units. Bars represent the mean ± SEM of 5 mice per group. Signiﬁcant diﬀerences (∗P<0.05, ∗∗P<0.01 or ∗∗∗P<0.001) are indicated by
asterisks.
In addition, IL-10-deﬁcient C3H mice from the same paren-
teralbreedingstocksbutmaintainedintwodiﬀerentfacilities
had signiﬁcant diﬀerences in histopathological scores at the
same age. These diﬀerences were attributed to the source
of diet and its ingredients and to the water treatment
(autoclaved or not) because health monitoring of the two
colonies indicates the same SPF status [26]. Berg and
coworkers reported small multifocal inﬁltrates, in lamina
propria of colon in 3-week-old IL-10−/− mice whereas 12-
week-old IL-10−/− mice had multifocal lesions and epithelial
hyperplasia in all regions of large intestine [19]. Thus, in
mice housed in our animal facility, the onset of enterocolitis
was delayed but the progression was faster.
In this study, we evaluated not only inﬂammatory
changes in the large intestine but also in the small intestine
of IL-10-deﬁcient mice. Although there was no visible
inﬂammation in the small intestines at 6 weeks of age,
the villus/crypt ratio was reduced and this alteration was
observed until adulthood (16 weeks of age). Altered vil-
lus/crypt morphology has been reported in a number of
immune-mediated bowel disorders, including celiac disease,
Crohn’s disease, and ulcerative colitis. This type of change is
duetoacceleratedepithelialturnoverandapoptosistriggered
by cytokines released from inﬁltrating inﬂammatory cells
and from enterocytes themselves [27]. This could contribute
to the inﬂammatory enteritis that we found in 16-week-old
IL-10−/− mice.
Smallintestinalmucosaharboursaparticularpopulation
of lymphocytes named intraepithelial lymphocytes (IELs).
IELs are in the ﬁrst line of mucosal surface intertwined
with epithelial cells, and the main subpopulations of IELs,
TCRαβ+ and TCRγδ+, are both described as involved in
inhibition of cytotoxic T cells (CTL). The intraepithelial
lymphocyte compartment probably provides a ﬁrst line of
defense against infectious pathogens attacking the surfaces
of the body and also provides a link between innate
and acquired immunity [25, 28]. TCRγδ+ IELs are also
related to immunoregulatory roles such as maintenance of
epithelial tissue integrity [25], oral tolerance induction [29],
and colitis modulation [30]. In acute colitis induced byClinical and Developmental Immunology 9
WT 
IL 10−/−
4 weeks 6 weeks 10 weeks 16 weeks
sIgA
15
10
5
0
μ
g
/
m
L
∗∗∗
∗∗∗
∗∗∗
∗
(a)
WT KO
0
0.5
1
1.5
2
(
a
.
u
.
)
C
o
n
t
r
o
l
I
m
m
u
n
e
G
a
v
a
g
e
C
.
 
f
e
e
d
i
n
g
C
o
n
t
r
o
l
I
m
m
u
n
e
G
a
v
a
g
e
C
.
 
f
e
e
d
i
n
g
Anti-Ova IgE
∗∗∗
∗∗∗ ∗∗∗ ∗∗∗
∗∗∗ ∗∗∗
(b)
0
0.5
1
1.5
2
WT KO
(
a
.
u
.
)
∗∗∗ ∗∗∗
∗∗∗
∗∗∗ ∗∗∗
∗∗∗
Anti-Ova IgG1
C
o
n
t
r
o
l
I
m
m
u
n
e
G
a
v
a
g
e
C
.
 
f
e
e
d
i
n
g
C
o
n
t
r
o
l
I
m
m
u
n
e
G
a
v
a
g
e
C
.
 
f
e
e
d
i
n
g
(c)
Figure 6: Secretory IgA and oral tolerance. Intestinal feces from 4-, 6-, 10-, or 16-week-old IL-10−/− mice were collected and total sIgA (a)
was measured by ELISA. 16-week-old IL-10−/− or wild-type mice received Ova either by gavage or by continuous feeding. Seven days later
mice were sensitized by an intraperitoneal (i.p.) injection of 0.2mL saline (0.9% NaCl) solution containing 10μg OVA (Sigma, St. Louis,
MO) adsorbed in 1mg aluminum hydroxide. Fourteen days later, animals received the same dose of OVA in PBS. Control animals received
0.2mL sterile saline. Anti-Ova IgE and IgG1 antibodies were measured by ELISA. A.U.: arbitrary units. Bars represent the mean ± SEM of 5
mice per group. Asterisks represent diﬀerence between groups (∗P<0.05 or ∗∗∗P<0.001).
administration of either 2,4,6-trinitrobenzene sulfonic acid
(TNBS) or DSS, a protective role of γδ T cells has been
demonstrated [30]. Our group has shown recently that the
frequency of γδ+ IELs is diminished in aged mice and
that this aging-associated change parallels a reduction in
susceptibility to oral tolerance induction [31]. In this study,
we observed that the frequency of TCRαβ+ and TCRγδ+ T
lymphocytes in the IEL compartment did not change (data
not shown), but there was a reduction in the frequency of
activated TCRγδ+ Thy1.2+ cells in IL-10-deﬁcient mice with
established inﬂammation. Since TCRγδ+ IELs are involved
in regulatory activities in the gut mucosa, this reduction can
representaninstanceofimmunoregulatoryfailureassociated
with disease development in IL-10-deﬁcient mice.
Classical studies reported that the enterocolitis in IL-
10-deﬁcient mice is associated with uncontrolled cytokine
production by activated macrophages and CD4+ Th1-like T
cells [19]. The excessive generation of IFN-γ-producing T
cells (Th1) driven by IL-12 produced by antigen-presenting
cells was described to be responsible for the initiation of
disease [32]. However, later studies revealed that IL-23, but
not IL-12, drives the intestinal inﬂammation in IL-10−/−
mice. A critical target of IL-23 is memory T cells, which
producetheproinﬂammatorymediatorsIL-17andIL-6[33].10 Clinical and Developmental Immunology
We showed that levels of IFN-γ were elevated in the colon
of 16-week-old but not of young IL-10−/− mice. Moreover,
6-week-old IL-10−/− mice had increased levels of IL-17A in
their colonic mucosa. These results are consistent with the
ﬁndingsthatIL-17Aisthecytokinethatinitiatetheintestinal
inﬂammation in IL-10−/− mice followed by an enhanced
production of IFN-γ. Th17 cells can convert to Th1 cells
through IL-17 induction of IL-12 and IL-23 production by
dendritic cells at colonic mucosa [34]. Recently, Mikami and
coworkers showed that cotransfer of the mixed Th1/Th17
CD4+ T cells from IL-10−/− with colitis with Th1 CD4+ T
cells from CD4+CD45high-induced RAG−/− mice with colitis
into RAG−/− mice ameliorate wasting disease. Thus, it seems
thatTh17cellscompetewithTh1cells,andthatpredominant
secretion of IFN-γ is related to more severe colitis [35].
Moreover, macrophages are usually activated by IFN-γ to
produceIL-6andthiscouldexplaintheconcomitantincrease
in IFN-γ and IL-6 levels in the colon of 16-week-old IL-
10−/− mice [36]. In light of these results, TGF-β production
in the colon of 10-week-old IL-10−/− mice may represent
an attempt to regulate inﬂammation by the direct regulatory
action of TGF-β. Indeed, production of IL-6 in the colon of
10-week-old IL-10−/− was not high. It is also remarkable that
the shift from IL-17A into IFN-γ production in the colonic
mucosa of IL-10−/− mice coincided with more severe colitis,
spreading of inﬂammation to the small intestine (Figure 1)
and deterioration in the clinical status of the animals.
Cytokine proﬁle was also evaluated in all segments of
the small intestine. We found enhanced levels of IL-17A
in the duodenum of 10-week-old IL-10−/− mice. On the
other hand, there were higher levels of TGF-β in the colon
at the same time point. At 16 weeks of age, TGF-β was
also produced in the proximal jejunum. Interestingly, the
enhanced IL-17A production observed at 10 weeks of age
disappeared at 16 weeks of age (Figure 4(b)). The detected
upregulation of TGF-β in 10-week-old mice could be an
immunoregulatory process triggered in the small intestine to
control inﬂammation. However, it was not a successful mod-
ulatory event since histological analysis of the small intestine
at that stage showed that inﬂammation was pronounced
in the colon and also in the small intestine. This suggests
that although TGF-β can be an important compensatory
mechanism in the immune homeostasis of IL-10-deﬁcient
mice, these animals show no other inﬂammatory disorder.
Nevertheless, in the gut mucosa, IL-10 seems to be critical
and overproduction of TGF-β was not enough to control
intestinal inﬂammation.
Despite the absent intestinal inﬂammation in young
mice, we found enhanced frequency of CD4+ T cells express-
ing a memory phenotype (CD44high) in the large intestinal
mucosa before the establishment of colitis (6 weeks of age).
Berg and coworkers showed that increased numbers of T-
cells were present in IL-10-deﬁcient mice already at 3 weeks
of age [19]. In a study using the Gαi2-deﬁcient mouse model
of ulcerative colitis, increased numbers of mucosal lympho-
cytes expressing the CD44high marker were isolated from
mice before the onset of colitis [21]. Presumably, the T cell
inﬂux into the colonic lamina propria is an important factor
in the subsequent establishment of colitis. In IL-10-deﬁcient
mice with severe disease, the high frequency of CD44high
was maintained. We had distinct results for T lymphocytes
expressing the early activation marker CD69+. There was
an enhanced frequency of CD69+ in both 129Sv/Ev wild-
type and IL-10−/− mice from 6 weeks to 16 weeks of age.
This indicates that an age-related increase in activated CD4+
lymphocytes that is consistent with other studies [31]a n d
that can be explained by the continuous exposure to antigens
under conventional housing. This seemed to be associated
with microbiota stimulation since there is no equivalent
changeinthefrequencyofactivatedCD4+ Tcellsinthesmall
intestine where bacterial colonization is much less intense.
Induced CD4+CD25+Foxp3+ T cells have already been
shownasimportantplayersinthehomeostasisofgutmucosa
[37]. A reduced frequency of CD4+CD25+Foxp3+ regulatory
T cells was found in the large intestine of mice as young
as 6 weeks old. This could be directly related to the IL-
10 deﬁciency. Moreover, IL-10 secreted by CD11b+CD11c+
dendriticcellsisafundamentalcytokineforthemaintenance
of Foxp3 expression in induced regulatory T cells in the
periphery during colitis development [38].
Our next step was to analyze the frequency of CD4+LAP+
T cells during colitis development in these mice. CD4+LAP+
T cells represent a subset of regulatory T cells express-
ing TGF-β bound to their membranes in its precursor
form (associated with the latent associated peptide, LAP).
CD4+CD25+LAP+ T cells have been shown to participate
in the control of intestinal inﬂammation in experimental
models of colitis [39] and CD4+LAP+ T cells, either express-
ing CD25 or not, have recently been reported as a distinct
subset of T cells [40]. Frequency of CD4+CD25+LAP+
was not aﬀected in young IL-10-deﬁcient mice. However
CD4+CD25+LAP+ T cells were decreased in IL-10-deﬁcient
mice at 16 weeks of age both in the colon and in the small
intestine. The decrease in frequency of CD4+CD25+LAP+ T
cells was observed in the small intestine of 16-week-old IL-
10−/− in the same time point of TGF-β augment in proximal
jejunum. Thus, it is likely that other cell types, including
macrophages and the gut epithelial cells, were responsible
for the production of TGF-β and not CD4+LAP+ T cells.
We also found enhanced frequencies of CD4+LAP+ Tc e l l s
in wild-type mice at 16 weeks of age when compared to the
frequencies found in 6-week-old mice. Our group described
similar data in a recent study on age-related alterations in
the gut mucosa. An increase in CD4+CD25+LAP+ cells was
observed in mesenteric lymph nodes and Peyer’s patches of
6- to 24-month-old mice when compared to young animals
(2-month-old), suggesting that these T cell subsets augment
after sexual maturity but remain stable afterwards [31].
Not only the cell-mediated but the humoral components
of the immune system have been implicated in the patho-
genesis of human and mouse models of IBD. Anticolon
antibodieshavebeendetectedinIL-2 −/− mice[41].Antibody
reactive with enteric microbiota such as Campylobacter
jejuni, have been identiﬁed in human patients, particularly
those with ulcerative colitis [42]. In this study, we ﬁnd
enhanced levels of serum IgG and IgA in IL-10-deﬁcient
mice with established and severe colitis, respectively. OurClinical and Developmental Immunology 11
ﬁndings are in agreement with other studies on IL-10-
deﬁcient mice. Kuhn and colleagues were the ﬁrst authors
to demonstrate elevated levels of serum IgG1 and IgA in
8-week-old IL-10−/− mice [15]. Davidson and coworkers
also showed the cross-reactivity of IL-10−/− mice serum Ig
with colon epithelial and nonepithelial cells in the majority
of sera tested. However, the same authors created the B
cell-deﬁcient (B−/−)s t r a i no fl L - 1 0 −/− mice and this mice
acquired a severe colitis analogous to that of lL-10−/− mice,
implying that B cells were not the primary mediator of
IBD in this model [17]. Therefore, we cannot say whether
that these alterations were a compensatory response to
the inﬂammation or that they were simply a phenomenon
related to inﬂammation of the colon. IL-10-deﬁcient mice
at the age of 4–6 weeks had a similar percentage of B cells
in thymus and spleen and normal B1 cell subset in the
peritoneum [15]. B1 cells were originally identiﬁed as CD5+
B cells [43]. Surprisingly, frequency of CD19+CD5+ cells was
increased in the lamina propria of small and large intestine
as well as in peritoneum and Peyer’s patches of 16-week-
old IL-10−/− mice. B1 cells from the peritoneum produce
predominantly IgM, but class switch to IgA has been shown
to occur in the B cell population [44]a n dlamina propria B1
cellsareresponsibleforatleasthalfofthesecretoryIgAinthe
gut mucosa [45]. Serum IgA levels enhanced concomitantly
with inﬂammation in IL-10−/− mice. Secretory IgA levels
were also higher at 10-week-old mice. Thus, it is reasonable
to speculate that B1 cells are the main source of this incre-
ment of IgA.
Oral tolerance is a major and common consequence
of oral administration of antigen [6]. Although several
mechanisms have been proposed to explain the induction,
production of anti-inﬂammatory cytokines such as TGF-
β and IL-10 and induction of regulatory T cells such as
CD4+CD25+Foxp3+ and CD4+LAP+ T cells seem to be
criticalfororaltoleranceinduction[46].Therewereprevious
and controversial reports on the role of IL-10 in this process.
Rizzo and coworkers showed that mice genetically engi-
neered to lack IL-4, IL-10 or both cytokines were refractory
to oral tolerance [47]. Later, Aroeira and coworkers showed
that in vivo depletion of IL-10 with monoclonal antibodies
did not aﬀect oral tolerance induction in mice [48]. In the
present study, we observed that oral tolerance to IgE could
be induced in 16-week-old IL-10-deﬁcient mice by the two
regimens of feeding used, gavage, and continuous feeding.
However, only continuous feeding of the antigen, but not
gavage, could lead to the suppression of anti-Ova IgG1.
Our group has previously described that continuous
administration of the antigen is an optimal protocol for oral
tolerance induction when compared to antigen administra-
tion by gavage [49]. Even aged mice (70-week-old), usually
refractory to oral tolerance by gavage, can be rendered
tolerant by continuous feeding of the antigen [50]. We
have also shown, in a previous study using mice with
ethanol-induced colitis, that oral tolerance induction to
speciﬁc serum IgG1 production was impaired in gavage-
fed mice [51]. As already reported, IgG1 is the most resis-
tant immunological parameter to suppression by mucosal
administration of proteins. Nasal administration of antigen
does not suppress speciﬁc anaphylactic serum IgG1, whereas
continuous feeding inhibits it very eﬃciently [52]. In this
study,weconﬁrmedthesepreviousdatashowingthatcontin-
uous feeding but not gavage was able to render diseased IL-
10-deﬁcient mice tolerant to ovalbumin when speciﬁc IgG1
antibodies were measured. Therefore, IL-10 deﬁciency and
severe inﬂammation in the gut mucosa seemed to decrease
but not abolish susceptibility to oral tolerance induction.
This result represents a key element in designing novel
therapeutic approaches for inﬂammatory bowel diseases.
Since these pathological conditions are generated by inﬂam-
mation, the suppressive modulatory properties of tolerance
procedures obtained by oral administration of disease-
related proteins would be an alternative. Oral tolerance to
target antigens has been successfully tested in many models
of other inﬂammatory illnesses such as autoimmune and
allergic diseases [6]. Our present data indicates that even
in the presence of severe colitis and enteritis, oral tolerance
approaches could be used as an alternative therapeutic
tool for inﬂammatory bowel diseases. Nevertheless, optimal
protocols of oral administration, such as continuous feeding,
would be a requirement for the use of such strategies.
In conclusion, we demonstrated that IL-10-deﬁcient
mice have a progressive and spontaneous inﬂammation with
marked alterations in the immune system. The absence of an
important anti-inﬂammatory cytokine such as IL-10 leads
to a dramatic defect of immunoregulation, with reduced
regulatory T lymphocytes in the gut mucosa, alterations in
immunoglobulins isotypes production and in the frequency
ofB1cells.Importantly,wealsoshowedthatalthoughseveral
mechanisms of immunoregulation were compromised in IL-
10-deﬁcient mice, oral tolerance induction could still be
induced. Our study also provides data showing that some
immunoregulatory mechanisms were still preserved and oral
tolerance could be induced even during overt inﬂammation.
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